S1PR1 and secondary progressive multiple sclerosis: In 2020, the selective S1PR1 and 5 modulator siponimod (trade name Mayzent®) received EU approval for treating adults suffering from SPMS with disease activity demonstrated by clinical relapses or imaging of inflammatory activity.